Jazz Pharmaceuticals plc’s filing revealed that its Chairman & CEO COZADD BRUCE C unloaded Company’s shares for reported $55000.0 on Jun 03 ’25. In the deal valued at $110.00 per share,500 shares were sold. As a result of this transaction, COZADD BRUCE C now holds 437,973 shares worth roughly $48.67 million.
Then, COZADD BRUCE C sold 500 shares, generating $53,950 in total proceeds. Upon selling the shares at $107.90, the Chairman & CEO now owns 438,473 shares.
Before that, COZADD BRUCE C bought 1,000 shares. Jazz Pharmaceuticals plc shares valued at $108,950 were divested by the Officer at a price of $108.95 per share.
UBS upgraded its Jazz Pharmaceuticals plc [JAZZ] rating to a Buy from a a Neutral in a research note published on March 07, 2025; the price target was increased to $179 from $145. A number of analysts have revised their coverage, including Cantor Fitzgerald’s analysts, who decreased its forecast for the stock in late February from “an Overweight” to “a Neutral”. Wells Fargo also remained covering JAZZ and has increased its forecast on February 13, 2025 with a “an Overweight” recommendation from previously “an Equal weight” rating. Morgan Stanley revised its rating on December 12, 2024. It rated JAZZ as “an Overweight” which previously was an “an Equal-weight”.
Price Performance Review of JAZZ
On Friday, Jazz Pharmaceuticals plc [NASDAQ:JAZZ] saw its stock jump 2.14% to $111.13. Over the last five days, the stock has gained 2.83%. Jazz Pharmaceuticals plc shares have fallen nearly -9.76% since the year began. Nevertheless, the stocks have risen 6.36% over the past one year. While a 52-week high of $148.06 was reached on 02/26/25, a 52-week low of $95.49 was recorded on 04/09/25. SMA at 50 days reached $109.58, while 200 days put it at $118.45.
Levels Of Support And Resistance For JAZZ Stock
The 24-hour chart illustrates a support level at 109.43, which if violated will result in even more drops to 107.72. On the upside, there is a resistance level at 112.34. A further resistance level may holdings at 113.54. The Relative Strength Index (RSI) on the 14-day chart is 53.77, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.81, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 16.79%. Stochastics %K at 66.67% indicates the stock is a holding.
The most recent change occurred on June 05, 2024 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $169 price target.
